Lymphocyte Subsets Changes in Children with Acute Lymphoblastic Leukemia during Chemotherapy

1 Aster JC, DeAngelo DJ. (2011): Chapter 21: Acute Leukemias. In: Pathophysiology of blood disorders, eds Bunn H, Aster J, The McGraw-Hill Companies, Inc., New York, pp. 244–259. Search in Google Scholar

2 Rytting ME, ed. (2013): Acute leukemia. Merck Manual Professional. Merck Sharp & Dohme Corp., Whitehouse Station. Search in Google Scholar

3 National Cancer Institute Age-Adjusted and Age-Specific SEER Cancer Incidence Rates, 2014–2018. [(accessed on 18 April 2021)]; Available online Search in Google Scholar

4 Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 371, 1030–1043 (2008). Search in Google Scholar

5 Pui CH, Carroll WL, Meshinchi S, Arceci RJ: Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 29, 551–565 (2011). Search in Google Scholar

6 Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–1955. doi: 10.1016/S0140-6736(12)62187-4. Search in Google Scholar

7 Malard F., Mohty M. Acute lymphoblasti leukaemia. Lancet. 2020; 395: 1146–1162. doi: 10.1016/S0140-6736(19)33018-1 Search in Google Scholar

8 Hunger S.P., Mullighan C.G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 2015;373:1541–1552. doi: 10.1056/NEJMra1400972. Search in Google Scholar

9 Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jonsson OG, Lausen B, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011; 29: 310–5. doi: 10.1200/JCO.2010.30.6829 Search in Google Scholar

10 Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122:170–8. doi: 10.1182/blood-2013-03-491621. Search in Google Scholar

11 Kosmidis S, Baka M, Bouhoutsou D, et al. Longitudinal assessment of immunological status and rate of immune recovery following treatment in children with ALL. Pediatr Blood Cancer.2008; 50(3): 528–32. Search in Google Scholar

12 Alanko S, Salmi TT, Pelliniemi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pedi atr HematolOncol.1994;11(3): 281–92. Search in Google Scholar

13 Eyrich M, Wiegering V, Lim A, Schrauder A, Winkler B, Schlegel PG. Immune function in children under chemotherapy for standard risk acute lymphoblastic leukaemia: a prospective study of 20 paediatric patients. Br J Haematol.2009; 147(3): 360–70. Search in Google Scholar

14 van Tilburg CM, van der Velden VH, Sanders EA, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition. LeukRes. 2011; 35(4): 484–91. Search in Google Scholar

15 Pietras W, Chaber R, Pela H, Trybucka K, Chybicka A. The recovery of immune system parameters in children following lymphoblastic leukemia therapy: preliminary report. Adv Clin Exp Med.2014; 23(1): 97–102. Search in Google Scholar

16 Rudant J, Lightfoot T, Urayama K, Petridou E, Dockerty J, Magnani C, Milne E, Spector LG, Ashton LJ, Dessypris N, Kang AY, Miller M, Rondelli R, Simpson J, Stiakaki E, Orsi L, Roman E, Metayer C, Infante-Rivard C, Clavel J: Childhood acute lymphoblastic leukemia and indicators of early immune stimulation: A childhood leukemia international consortium study. Am J Epidemiol 181, 549–562 (2015). Search in Google Scholar

17 Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017; 188: 333–341. Search in Google Scholar

18 Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2014 Jan;99(1):103-10. doi: 10.3324/haematol.2013.090225. Epub 2013 Aug 2. PMID: 23911702; PMCID: PMC4007934. Search in Google Scholar

19 WuCP,QingX,WuCY,ZhuH,ZhouHY.Immunophenotypeandincreased presence of CD4(+) CD25(+) regulatory T cells in patients with acute lymphoblastic leukemia. Oncol Lett. (2012) 3: 421–4. doi: 10.3892/ol.2011.499 Search in Google Scholar

20 Salem ML, El-Shanshory MR, Abdou SH, Attia MS, Sobhy SM, Zidan MF, et al. Chemotherapy alters the increased numbers of myeloid derived suppressor and regulatory T cells in children with acute lymphoblastic leukemia. ImmunopharmacolImmunotoxicol. (2018) 40: 158–67. doi: 10.1080/08923973.2018.1424897 Search in Google Scholar

21 van Tilburg CM, van der Velden VH, Sanders EA, Wolfs TF, Gaiser JF, de Haas V, et al. Reduced versus intensive chemotherapy for childhood acute lymphoblastic leukemia: impact on lymphocyte compartment composition. Leuk Res. (2011) 35: 484–91. doi: 10.1016/j.leukres.2010. 10.005 Search in Google Scholar

22 Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. (2019) 9: 492–9. doi: 10.1158/2159-8290.CD-18-1314 Search in Google Scholar

23 Rheinländer A, Schraven B, Bommhardt U. CD45 in human physiology and clinical medicine. Immunol Lett. 2018 Apr; 196: 22–32. doi: 10.1016/j.imlet.2018.01.009. Epub 2018 Jan 31. PMID: 29366662. Search in Google Scholar

24 Ballo O, Tarazzit I, Stratmann J, Reinheimer C, Hogardt M, Wichelhaus TA, et al. Colonization With Multidrug Resistant Organisms Determines the Clinical Course of Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy. PloS One (2019) 14(1): e0210991. doi: 10.1371/journal.pone.0210991 Search in Google Scholar

25 Chinen J, Shearer WT. Secondary Immunodeficiencies, Including HIV Infection. J Allergy Clin Immunol (2010) 125(2 Suppl.):S195–203. doi: 10.1016/j.jaci.2009.08.040 Search in Google Scholar

26 Na IK, Buckland M, Agostini C, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019; 102(6): 447–456. Search in Google Scholar

27 Joanna Zawitkowska, Katarzyna Drabko, Anna Szmydki-Baran, Agnieszka Zaucha-Prażmo, Monika Lejman, Krzysztof Czyżewski, Infectious profile in children with ALL during chemotherapy: A report of study group for infections, J Infect Chemother. 2019 Oct;25(10): 774–779. doi: 10.1016/j.jiac.2019.04.005. Epub 2019 May 14. Search in Google Scholar

28 Stephen Jolles, Mauricette Michallet,Carlo Agostini, Michael Albert,David Edgar,Roberto Ria,Livio Trentin,Elisabeth Clodi,Vincent Lévy. AN INTERNATIONAL DELPHI CONSENSUS BUILDING APPROACH TO PATIENT ASSESSMENT AND USE OF IMMUNOGLOBULIN TREATMENT FOR SECONDARY IMMUNE DEFICIENCIES IN HEMATOLOGICAL MALIGNANCY. EHA Library. Albert M. 06/12/20; 297829; PB1913 Search in Google Scholar

29 C L Mackall, T A Fleisher et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer, Blood. 1994 Oct 1; 84(7): 2221–8. Search in Google Scholar